June 5th 2021, 3:00pm
Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.
June 5th 2021, 1:00pm
The addition of a novel drug to the chemotherapies gemcitabine and cisplatin significantly improved a survival outcome in patients with a rare form of head and neck cancer, compared with chemotherapy alone.
April 30th 2021, 3:22pm
View the entire 2021 Extraordinary Healer® Award for Oncology Nursing virtual presentation here!
March 16th 2021, 1:00pm
An expert discusses the potential that several novel therapies hold in treating metastatic breast cancer, including PARP inhibitors, immunotherapy and antibody drug conjugates. Each therapy type has an FDA-approved option to potentially provide patients with better outcomes and quality of life.
March 15th 2021, 1:00pm
In the field of lung cancer, a number of current studies evaluating the efficacy of adoptive cellular therapies may one day offer patients with non-small cell lung cancer a “high risk, high reward” treatment option, according to Dr. Ben Creelan of the Moffitt Cancer Center.
March 13th 2021, 3:00pm
View the full CURE Educated Patient Multiple Myeloma Summit on demand.
March 12th 2021, 10:00pm
As the population ages, the incidence of older adults being diagnosed with lung cancer is increasing, though data on how to specifically treat this population are lacking.
March 11th 2021, 2:00pm
Targeted therapies that attack cancer in a more precise way than traditional chemotherapy are being used more often in the field of breast cancer, but the solution in utilizing them lies within the patient-oncologist relationship, according to an expert from the Massachusetts General Hospital Cancer Center.
March 10th 2021, 7:00pm
An expert discusses ways that small cell lung cancer is diagnosed, how to treat it and how to pivot if the disease spreads or recurs. He also focuses on efforts in the clinical trial space to potentially treat patients more effectively.
March 10th 2021, 2:00pm
Mindfulness practices have been associated with improved mental health outcomes in patients with cancer. Here, an expert shares tips on how patients can strengthen their “mindfulness muscle.”
March 9th 2021, 4:00pm
With more than 4 million breast cancer survivors in the U.S., survivorship care and understanding what happens to patients after surviving is of the utmost importance. An expert explains some side effects survivors may experience and treatments to help.
March 7th 2021, 3:00pm
View the full CURE Educated Patient Breast Cancer Summit on demand.
March 6th 2021, 3:00pm
View the full CURE Educated Patient Lung Cancer Summit on demand.
February 23rd 2021, 10:00pm
A cancer diagnosis often comes with concerns of what’s next for patients. One concern is how they’re going to afford their treatments. Here, a panel of experts discuss what options are available.
February 23rd 2021, 7:00pm
There are two myths that patients with cancer believe when it comes to being health advocates. Here, a panel of experts look to dispel those myths to help patients become better advocates.
February 23rd 2021, 2:00pm
Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.
February 19th 2021, 10:00pm
There are several health equity barriers in patients with cancer, one of which involves adequate access to clinical trials. Here, a panel of experts and a cancer survivor discuss ways to improve access.
February 18th 2021, 2:00pm
The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.
February 15th 2021, 10:00pm
Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.
February 13th 2021, 10:00pm
The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.
February 13th 2021, 6:00pm
Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.
February 13th 2021, 4:00pm
For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.
February 12th 2021, 10:20pm
Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.
February 12th 2021, 8:45pm
The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
February 12th 2021, 6:30pm
Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.
February 11th 2021, 9:56pm
Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.
February 11th 2021, 8:49pm
A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.
February 11th 2021, 6:59pm
The combination of Lenvima plus everolimus was found to be an acceptable treatment option for patients who have previously received immunotherapy for clear cell renal cell carcinoma, according to the findings of an exploratory analysis of a phase 2 trial presented virtually at the 2021 ASCO Genitourinary Cancers Symposium.
December 19th 2020, 3:00pm
View the full CURE Educated Patient Women's Cancer Summit on demand.
December 16th 2020, 7:00pm
View all three sessions of the CURE Educated Patient Lung Cancer Summit here!